Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.40 |
| ▸ | FURIN | P09958 | 5/20 | 0.37 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | NPY1R | P25929 | 1/20 | 0.33 |
| ▸ | NPY2R | P49146 | 1/20 | 0.33 |
| ▸ | NPY4R | P50391 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.32 |
| ▸ | CHRNG | P07510 | 1/20 | 0.32 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.32 |
| ▸ | CHRND | Q07001 | 1/20 | 0.32 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.32 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22128021 | 1.00 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL24476142 | 1.00 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL32667737 | 1.00 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL22138625 | 0.99 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL23943282 | 0.99 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL24224636 | 0.99 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL25450085 | 0.99 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL16946352 | 0.99 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL27197502 | 0.99 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL24476140 | 0.94 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3972649-B1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| US-20260027220-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2026-01-29 | — | — | US | disclosed |
| US-20250339547-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| US-20240269304-A1 | BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | LES LABORATOIRES SERVIER (FR) | 2024-08-15 | — | — | US | disclosed |
| EP-4406555-A2 | ANTIBODIES TO PMEL17 AND CONJUGATES THEREOF | Novartis AG (CH) | 2024-07-31 | — | — | EP | disclosed |
| US-20240189439-A1 | ANTIBODIES TO PMEL17 AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2024-06-13 | — | — | US | disclosed |
| US-20240042051-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | LES LABORATOIRES SERVIER (FR) | 2024-02-08 | — | — | US | disclosed |
| WO-2023225320-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225336-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| US-11779649-B2 | Antibodies to PMEL17 and conjugates thereof | NOVARTIS AG (CH) | 2023-10-10 | — | — | US | disclosed |
| WO-2022115451-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022115477-A1 | BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2022-06-02 | — | — | WO | disclosed |
| EP-3972651-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |
| CN-113348181-A | DC-SIGN antibody conjugates comprising a STING agonist | 诺华股份有限公司 | 2021-09-03 | — | — | CN | disclosed |
| CN-113195541-A | Antibodies against PMEL17 and conjugates thereof | 诺华股份有限公司 | 2021-07-30 | — | — | CN | disclosed |
| US-20210170043-A1 | DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS | CHINOOK THERAPEUTICS, INC. | 2021-06-10 | — | — | US | disclosed |
| WO-2020236817-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020236825-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2020-11-26 | — | — | WO | disclosed |
| US-20200197528-A1 | ANTIBODIES TO PMEL17 AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2020-06-25 | — | — | US | disclosed |
| CN-110799218-A | Antibody conjugates comprising STING agonists | 诺华股份有限公司 | 2020-02-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11779649-B2 | Antibodies to PMEL17 and conjugates thereof | GNA15, GNA11, EEA1 | FAP 1761/4885FURIN 2986/4885MAP1LC3B 817/4885 |
| US-20260027220-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | EPHA2, EPHA1, EPHB1 | FAP 3796/4885FURIN 2969/4885MAP1LC3B 1602/4885 |
| US-20250339547-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | MET, BCL3, BCL9 | FAP 1308/4885FURIN 1982/4885MAP1LC3B 738/4885 |
| US-20210170043-A1 | DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS | STING1, TLR9, TLR3 | FAP 4053/4885FURIN 1569/4885MAP1LC3B 1393/4885 |
| US-20240042051-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | MCL1, CD58, LENG8 | FAP 4102/4885FURIN 2649/4885MAP1LC3B 686/4885 |
| US-20240269304-A1 | BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | BCL3, BCL9, BCL2L10 | FAP 3283/4885FURIN 2283/4885MAP1LC3B 882/4885 |
| US-20200197528-A1 | ANTIBODIES TO PMEL17 AND CONJUGATES THEREOF | GNA15, GNA11, EEA1 | FAP 1835/4885FURIN 2640/4885MAP1LC3B 590/4885 |
| US-20240189439-A1 | ANTIBODIES TO PMEL17 AND CONJUGATES THEREOF | GNA15, GNA11, EEA1 | FAP 1835/4885FURIN 2640/4885MAP1LC3B 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.